Posted by Michael Wonder on 04 May 2023
Access to cancer medicines in the UK
1 May 2023 - On 31 January 2020, the UK formally ended it's 47 year membership of the EU. As a part of this, the Medicines and Healthcare products Regulatory Agency (MHRA) withdrew from the EMA.
Over the past 3 years, and as the UK's standalone regulator, the MHRA has implemented many changes, but announcements on 24 January and 21 March 2023, herald the largest shake-up of trial regulation in 20 years.
With the MHRA solely at the helm of marketing authorisation of new medicines, how has Brexit affected access to the latest cancer treatments for patients in the UK?
